de Torres IM - Search Results

1

The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.

Morote J, Schwartzmann I, Celma A, Roche S, de Torres IM, Mast R, Semidey ME, Regis L, Santamaria A, Planas J, Trilla E. Morote J, et al. Among authors: de torres im. BJU Int. 2022 May;129(5):627-633. doi: 10.1111/bju.15568. Epub 2021 Aug 25. BJU Int. 2022. PMID: 34375498

2

[Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate].

Morote J, Encabo G, Andreu J, de Torres I. Morote J, et al. Med Clin (Barc). 1996 Dec 7;107(20):795-6. Med Clin (Barc). 1996. PMID: 9019610 Spanish. No abstract available.

3

Measurement of free PSA in the diagnosis and staging of prostate cancer.

Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J. Morote J, et al. Int J Cancer. 1997 May 29;71(5):756-9. doi: 10.1002/(sici)1097-0215(19970529)71:5<756::aid-ijc11>3.0.co;2-6. Int J Cancer. 1997. PMID: 9180142 Free article.

4

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.

Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J. Morote J, et al. J Urol. 1997 Aug;158(2):502-4. J Urol. 1997. PMID: 9224333

5

Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR.

Schwartz S Jr, Caceres C, Morote J, De Torres I, Rodriguez-Vallejo JM, Gonzalez J, Reventos J. Schwartz S Jr, et al. Int J Cancer. 1998 May 18;76(4):464-7. doi: 10.1002/(sici)1097-0215(19980518)76:4<464::aid-ijc3>3.0.co;2-p. Int J Cancer. 1998. PMID: 9590118 Free article.

6

Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride.

Schwartz S Jr, Caceres C, De Torres I, Morote J, Rodriguez-Vallejo JM, Gonzalez J, Reventos J. Schwartz S Jr, et al. Int J Cancer. 1998 May 18;76(4):519-22. doi: 10.1002/(sici)1097-0215(19980518)76:4<519::aid-ijc13>3.0.co;2-2. Int J Cancer. 1998. PMID: 9590128 Free article.

7

Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis.

Schwartz S Jr, Caceres C, Morote J, De Torres I, Rodriguez-Vallejo JM, Gonzalez J, Reventos J. Schwartz S Jr, et al. Int J Oncol. 1999 Feb;14(2):367-71. doi: 10.3892/ijo.14.2.367. Int J Oncol. 1999. PMID: 9917515

8

[Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].

Morote J, Lorente JA, Raventós CX, López MA, Encabo G, De Torres I, López M, De Torres JA. Morote J, et al. Actas Urol Esp. 1998 Nov-Dec;22(10):835-9. Actas Urol Esp. 1998. PMID: 9949572 Clinical Trial. Spanish.

9

Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time.

Morote J, López M, Encabo G, de Torres I. Morote J, et al. Eur Urol. 1999 Apr;35(4):294-7. doi: 10.1159/000019864. Eur Urol. 1999. PMID: 10087391

10

The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.

Morote J, Encabo G, Lopez MA, De Torres IM. Morote J, et al. Among authors: de torres im. BJU Int. 1999 Jun;83(9):1003-6. doi: 10.1046/j.1464-410x.1999.00085.x. BJU Int. 1999. PMID: 10368244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page